Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas

ABSTRACT: Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas

PROVIDER: PRJNA1019760 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26140776.fastq.gz	Fastqsanger.gz
	SRR26140777.fastq.gz	Fastqsanger.gz
	SRR26140778.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas

Project description:Purpose: Patients with advanced soft-tissue sarcomas (STSs) exhibit a poor prognosis and have few therapeutic options. DNA-dependent protein kinase catalytic subunit (DNA-PK) is a multifunctional serine—threonine protein kinase that plays a crucial role in DNA double-strand damage repair via nonhomologous end joining (NHEJ). Experimental design: To investigate the therapeutic potential of DNA-PK targeting in STS, we first evaluated the prognostic value of DNA-PK expression in two large cohorts of patients with STS. We then used the potent and selective DNA-PK inhibitor AZD7648 compound to investigate the antitumor effect of the pharmacological inhibition of DNA-PK in vitro via MTT, apoptosis, cell cycle, and proliferation assays. In vivo studies were performed with patient-derived xenograft models to evaluate the effects of AZD7648 in combination with chemotherapy or ionizing radiation on tumor growth. The mechanisms of sensitivity and resistance to DNA-PK inhibition were investigated by using a genome-wide CRISPR-Cas9 positive screen. Results: DNA-PK overexpression is significantly associated with poor prognosis in patients with sarcomas. Selective pharmacological inhibition of DNA-PK strongly synergizes with radiation- and doxorubicin-based regimen in sarcoma models. By using a genome-wide CRISPR-Cas9 positive screen, we identified genes involved in sensitivity to DNA-PK inhibition. Conclusion: DNA-PK inhibition deserves clinical investigation to improve response to current therapies in patients with sarcoma

2023-09-25 | GSE243758 | GEO

20 human soft-tissue sarcomas (TMT)

Project description:SCX fractiond, TMT labeled pleomorphic soft-tissue sarcomas. 32 raw files (8x4) plus 8 pools (also TMT labeled) corresponding to each SCX fraction are submitted. The latter were used to propagate identifications across the runs.

2020-01-27 | PXD000617 | Pride

Bulk RNA-sequencing of soft tissue sarcomas from patients undergoing chemotherapy and/or immunotherapy

Project description:The tumor microenvironment plays a crucial role in soft tissue sarcoma development and response to therapy. We performed bulk RNA-sequencing of tumors from patients with soft tissue sarcomas undergoing chemotherapy and/or immunotherapy to identify gene expression signatures associated with response to treatment.

2023-12-12 | GSE213065 | GEO

The Proteomic Landscape of Soft Tissue Sarcomas

Project description:Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of formalin-fixed paraffin embedded tumour specimens from 321 STS patients representing 11 histological subtypes.

2023-05-09 | PXD036226 | Pride

Spatial transcriptomics analysis of soft tissue sarcomas.

Project description:The tumor microenvironment plays a crucial role in soft tissue sarcoma development and response to therapy. We used spatial transcriptomics to analyze the spatial distribution of malignant, immune, and other stromal cells present within soft tissue sarcomas.

2023-12-12 | GSE212526 | GEO

Expression data from human soft tissue sarcomas with complex genomics

Project description:Differentially expressed genes between 171 human soft tissue sarcomas with complex genomics

2010-09-09 | GSE23980 | GEO

Clinical implications and molecular features of extracellular matrix networks in soft tissue sarcomas

Project description:The landscape of extracellular matrix (ECM) alterations in soft tissue sarcomas (STS) remains poorly characterised. We aimed to investigate the tumour ECM and adhesion signalling networks present in STS and their clinical implications.

2024-05-07 | PXD049373 | Pride

Clinical implications and molecular features of extracellular matrix networks in soft tissue sarcomas

2024-05-07 | PXD049383 | Pride

RNA-sequencing of primary soft tissue sarcomas and cell lines with ATRX deletion

Project description:RNA sequencing of a primary tumors from a sarcoma genetically engineerted mouse model with activation of oncogenic Kras, deletion of p53 and deletion of Atrx, as compared to control sarcomas with identical genetic alterations but with wild-type Atrx. Tumors were either untreated or recieved 20 Gy of ionizing radiation and were harvested at 4 hrs, 3 day, or 6 day timepoints post treatment. For cell lines, isogenic ATRX wild-type (WT) and ATRX knockout (KO) paired isogenic cell lines treated with either 1.)interferon stimulatory DNA (ISD) and harvested 24 hours after treatment, 2)4 Gy ionizing radiation and harvested 36 hours after treatment, or 3) untreated control. These experiments help determine the differential impact of ATRX mutational status on cGAS-STING and type-I interferon signaling in soft tissue sarcoma.

2021-03-06 | GSE167537 | GEO

Spatial transcriptomics analysis of soft tissue sarcomas.

Project description:Spatial transcriptomics analysis of soft tissue sarcomas.

| PRJNA875908 | ENA